According to the stock network, on the evening of October 24, 2021, *st Jitang issued an announcement: it said that it had received the "Advance Notice of Administrative Penalties and Market Prohibition" from the China Securities Regulatory Commission. After ascertaining that the CSRC found that the facts of *st Jitang's suspected illegality were as follows: There were false records in Tongjitang's "2016 Annual Report", "2017 Annual Report" and "2018 Annual Report", which inflated operating income, operating costs, sales and management expenses, resulting in false records in the total inflated profits of 680 million yuan, 920 million yuan and 830 million yuan from 2016 to 2018, respectively. The inflated income from other businesses was RMB386 million and the total inflated profit was RMB386 million. Shanghai lawyer Yu Qiang introduced to the stock network that financial fraud is a false statement, and investors can sue the issuer and relevant responsible persons for civil compensation. According to the interpretation of the stock network, the registration of investor claims against Tongjitang has been launched, and the mini program "stock network" platform accepts investor registration.
Tongjitang's main business is pharmaceutical wholesale, retail distribution, and non-pharmaceutical sales. The company's main source of performance is the pharmaceutical circulation business. In May 2016, Tongjitang was restructured and listed on the backdoor Xinjiang Hop Co., Ltd., and since then, Tongjitang's performance has been fraudulent almost every year. After deducting the inflated net profit, Tongjitang's net profit was negative for four consecutive years from 2017 to 2020. In the first half of this year, the company's net profit attributable to the mother was a loss of 64.77 million yuan.
The stock network reminds investors to pay attention to the following issues:
First, the claim conditions are further refined
As the results of the investigation paid the surface, the stock network learned that the conditions for investors to claim compensation from Tongjitang were further clarified. Shanghai Yu Qiang, a lawyer who cooperates with the stock network, believes that investors who bought Tongjitang (*st Jitang, 600090) shares before April 22, 2017 to April 28, 2020, and sold or continued to hold shares after April 28, 2020, can register or initiate claims on their own in the Mini Program "Stock Network".
2. Claim items
Article 30 of the Several Provisions stipulates that the scope of civil compensation liability borne by the perpetrator of the misrepresentation in the securities trading market is limited to the losses actually incurred by the investor as a result of the misrepresentation. The actual loss of the investor includes: (i) the loss of the investment difference; (ii) the commission and stamp duty of the loss of the investment difference. The interest on the funds mentioned in the preceding paragraph shall be calculated from the date of purchase to the date of sale of securities or the base date, according to the interest rate of the bank's demand deposit for the same period.
According to Tianyancha, *st Jitang, the full name of the company is Xinjiang Tongjitang Health Industry Co., Ltd., founded on April 26, 1993, listed on the Shanghai Stock Exchange on June 16, 1997, the current general manager Li Qing, the main business is drugs, medical devices and health-related products wholesale and retail distribution.
